Des Roches A, Paradis L, Bougeard Y H, Godard P, Bousquet J, Chanez P
Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France.
J Allergy Clin Immunol. 1996 Sep;98(3):522-7. doi: 10.1016/s0091-6749(96)70085-4.
Medications can modulate the results of skin prick tests (SPTs). Short-term corticosteroid therapy does not alter IgE-mediated skin tests, but the impact of long-term oral corticosteroid therapy on SPT results is unclear. A prospective study was carried out in patients with steroid-dependent asthma who received oral corticosteroids for a long period to determine whether this treatment reduced skin test reactivity.
Thirty-three patients with steroid-dependent asthma (median age, 59 years) were compared with 66 patients with asthma who served as a control group, matched for age, sex, and atopic status. SPTs with codeine phosphate and a screening battery of standardized allergen extracts were performed before commencement and after at least 1 year of daily oral prednisone treatment (median duration, 2 years; median daily dose, 20 mg).
Fifteen patients with corticosteroid-dependent asthma were allergic before treatment, and their sensitization was not changed by long-term treatment with oral corticosteroids. The median wheal diameters induced by codeine phosphate were similar in both groups. The median wheal diameters induced by allergens, and more specifically, by Dermatophagoides pteronyssinus and D. farinae were similar in both groups and did not change in the steroid group after treatment.
Systemic corticosteroid therapy (prednisone, 10 to 60 mg/day) for 2 or more years does not seem to alter SPT reactivity.
药物可调节皮肤点刺试验（SPT）的结果。短期糖皮质激素治疗不会改变IgE介导的皮肤试验，但长期口服糖皮质激素治疗对SPT结果的影响尚不清楚。对长期接受口服糖皮质激素治疗的激素依赖型哮喘患者进行了一项前瞻性研究，以确定这种治疗是否会降低皮肤试验反应性。
将33例激素依赖型哮喘患者（中位年龄59岁）与66例哮喘患者作为对照组进行比较，对照组在年龄、性别和特应性状态方面进行了匹配。在开始每日口服泼尼松治疗前（中位疗程2年；中位日剂量20mg）和至少1年后，用磷酸可待因和一组标准化变应原提取物进行SPT。
15例激素依赖型哮喘患者在治疗前过敏，长期口服糖皮质激素治疗后其致敏情况未改变。两组中磷酸可待因诱导的风团直径中位数相似。变应原诱导的风团直径中位数，更具体地说，粉尘螨和屋尘螨诱导的风团直径中位数在两组中相似，且治疗后激素组未发生变化。
2年或更长时间的全身糖皮质激素治疗（泼尼松，10至60mg/天）似乎不会改变SPT反应性。
